# CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

> **NCT07268794** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 112 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Prostate Cancer (Adenocarcinoma)
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

## Interventions

- **DRUG:** Androgen Deprivation Therapy (ADT)
- **DRUG:** Docetaxel
- **DRUG:** PARP Inhibitors and Other Systemic Agents
- **PROCEDURE:** Radical Prostatectomy
- **RADIATION:** Prostate Radiotherapy

## Key facts

- **NCT ID:** NCT07268794
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268794, "CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07268794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*